https://www.selleckchem.com/products/pf-543.html
Genomic signatures, such as EndoPredict , may help clinicians to decide which adjuvant treatment is the most appropriate. We propose the EndoPredict assay for unclear cases of adjuvant treatment in patients treated in our comprehensive cancer center. We prospectively and retrospectively report the decision of adjuvant treatment before and after the EndoPredict assay, respectively, compared to the PREDICT's tool scores. From November 2016 to March 2019, 159 breast cancer tumors were analyzed and presented before and after the EndoPredict
Like
Comment
Share
